Orthofix Medical (NASDAQ:OFIX) Director John Henneman III Purchases 5,000 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) Director John Henneman III acquired 5,000 shares of the stock in a transaction dated Thursday, May 7th. The shares were acquired at an average cost of $12.26 per share, with a total value of $61,300.00. Following the completion of the transaction, the director owned 90,809 shares in the company, valued at approximately $1,113,318.34. This represents a 5.83% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Orthofix Medical Trading Down 3.5%

OFIX opened at $11.65 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.43 and a current ratio of 2.87. Orthofix Medical Inc. has a one year low of $10.24 and a one year high of $16.99. The company has a market cap of $467.63 million, a P/E ratio of -7.72 and a beta of 0.79. The business’s 50-day simple moving average is $12.20 and its 200-day simple moving average is $13.88.

Orthofix Medical (NASDAQ:OFIX) last posted its earnings results on Tuesday, May 5th. The medical device company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.16. The firm had revenue of $196.71 million during the quarter, compared to analysts’ expectations of $196.40 million. Orthofix Medical had a negative return on equity of 13.44% and a negative net margin of 7.27%. As a group, equities research analysts expect that Orthofix Medical Inc. will post -1.57 EPS for the current fiscal year.

Key Headlines Impacting Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital Management, a major shareholder, bought about 184,900 shares of Orthofix Medical across May 5-7 for roughly $2.23 million, increasing its stake to about 3.85 million shares. That kind of repeated insider accumulation often signals confidence in the company’s outlook and can support the stock. Article: Insider Buying: Orthofix Medical (NASDAQ:OFIX) Major Shareholder Purchases 30,000 Shares of Stock
• Positive Sentiment: Orthofix posted first-quarter results that beat expectations, reporting a smaller-than-expected loss per share and revenue roughly in line with estimates. Investors may view the earnings beat as a sign that performance is holding up better than feared. Article: Orthofix Medical earnings report
• Neutral Sentiment: Analysts maintained a consensus view of roughly Hold, but the average price target is $17.25, which is above recent trading levels and suggests some upside if execution improves. Article: Orthofix Medical Inc. (NASDAQ:OFIX) Just Reported, And Analysts Assigned A US$17.25 Price Target
• Neutral Sentiment: Another report noted Engine Capital’s purchase of 30,000 shares for about $365,400, reinforcing the theme of insider confidence, though this is part of the same buying trend already reflected above. Article: Insider Buying: Orthofix Medical (NASDAQ:OFIX) Major Shareholder Purchases 30,000 Shares of Stock
• Negative Sentiment: Despite the earnings beat, Orthofix remains unprofitable and faces margin pressure, and the FDA’s reclassification of bone growth stimulators could increase competitive pressure in a key product category. Those issues may be limiting enthusiasm around the stock. Article: FDA reclassifies bone growth stimulators

Wall Street Analyst Weigh In

A number of research firms recently commented on OFIX. TD Cowen began coverage on shares of Orthofix Medical in a research report on Tuesday, January 27th. They issued a “hold” rating and a $14.00 target price on the stock. Stifel Nicolaus reduced their price target on shares of Orthofix Medical from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Wall Street Zen downgraded shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Barrington Research reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Orthofix Medical in a report on Friday, April 10th. Finally, Canaccord Genuity Group cut their target price on Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $17.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC raised its holdings in shares of Orthofix Medical by 67.7% in the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock valued at $333,000 after buying an additional 8,241 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Orthofix Medical by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after buying an additional 1,213 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Orthofix Medical during the first quarter worth about $1,076,000. Strs Ohio acquired a new position in Orthofix Medical in the 1st quarter valued at about $150,000. Finally, JPMorgan Chase & Co. raised its stake in Orthofix Medical by 15.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 193,549 shares of the medical device company’s stock valued at $2,158,000 after acquiring an additional 26,123 shares during the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.